Prevention and Research of Hypertension in Human Clinical

Junhui Jiang

《World Scientific Research Journal》 7卷9期 (2021/09) Pp. 183-187

https://doi.org/10.6911/WSRJ.202109_7(9).0025

摘要

In the past few decades, the prevalence of hypertension in our population has been increasing. The results of a national survey in 2000 showed that the prevalence rate of adult hypertension in my country was 18.8%. Compared with 1990, the awareness rate, treatment rate and control rate of hypertension have improved, but it is still at a low level compared with developed countries. In some communities, the control rate after hypertension management exceeds 60%. In general, the blood pressure reduction target for hypertensive patients is ＜140/90mmHg (1mmHg=0.133kpa), and the blood pressure reduction target for the elderly over 65 years old is ＜150/90mmHg, and it can be further reduced to ＜140/90mmHg if it can be tolerated; diabetes mellitus The blood pressure goal of kidney disease and coronary heart disease is ＜130/80mmHg; the management of high‐risk patients should be individualized. Improvements in lifestyle, such as salt restriction, smoking cessation, weight loss, alcohol restriction, increased potassium intake and physical activity, are meaningful for the prevention and control of high blood pressure. Five categories of antihypertensive drugs: calcium antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, diuretics, β‐receptor blockers and fixed compound preparations can be used as initial or maintenance treatment of hypertension choose. Hypertension in special populations requires special treatment, such as children, the elderly, pregnancy, and various cardiovascular complications. Due to differences in health and medical policies and levels, during the implementation of the guidelines, two different levels of recommendations (standard recommendations and basic recommendations) are recommended to allow the physician in charge to make appropriate choices.

關鍵字

Hypertension ； Drug therapy ； Disease management

參考文獻

Chen CM, Zhao W, Yang Z, et al. The role of dietary factors inchronic disease control in China[J].Obes Rev,2008,9(Suppl 1):100-103.

Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronaryand stroke events with atorvastatin in hypertensive patients whohave average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid loweringarm (ASCOT-LLA): a multicentre randomised controlled trial[.Lancet,2003,361(9364):1149-1158.

The ALLHAT Officers and Coordinators for the ALLHAT Col-laborative Research Group. Major outcomes in moderately hy-percholesterolemic，hypertensive patients randomized to pravas-tatin vs usual care.The antihypertensive and lipid-loweringtreatment to prevent heart attack trial (ALLHAT-LLT)[J].JAMA,2002,288(23):2998-3007.

Wang Longde. Survey results [M] // Wang Longde. One of the 2002 Comprehensive Reports of the Survey Report on Nutrition and Health Status of Chinese Residents. Beijing: People's Medical Publishing House, 2005:53-57.

Zhou Beifan. Diet and Cardiovascular Disease [M] // Zhou Beifan, Wu Xigui. Cardiovascular disease epidemiology and population prevention. Beijing: People's Medical Publishing House, 1993: 49-60.